TIDMDNL

RNS Number : 4038C

Diurnal Group PLC

11 October 2022

Diurnal Group PLC

("Diurnal" or the "Company")

Block Admission Application

Diurnal Group PLC (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that an application has been made to the London Stock Exchange for a block admission of 1,171,533 ordinary shares of 5 pence each ("Ordinary Shares") to be admitted to trading on AIM ("Block Admission").

The Block Admission relates to Ordinary Shares that will be issued from time to time in connection with the Company's share plans, including satisfying outstanding options already issued under the Diurnal Share Option Scheme 2015, options issued on the same terms as those issued under the Company's long term incentive plan or share options issued in September 2015. All Ordinary Shares issued pursuant to the Block Admission above will rank pari passu with the existing Ordinary Shares.

It is expected that the Block Admission will become effective on or around 13 October 2022. The Company will make six-monthly announcements of the utilisation of the block admission, in line with its obligations under AIM Rule 29.

For further information, please contact:

   Diurnal Group PLC                                                      020 3727 1000 

Richard Bungay, Interim Chief Executive Officer

FTI Consulting (Media and Investor Relations) 020 3727 1000

Simon Conway

Victoria Foster Mitchell

Alex Davis

   Panmure Gordon (Nomad and Broker)             02 0 7886 2500 

Freddy Crossley

Emma Earl

Rupert Dearden

About Diurnal

Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

For further information please visit: www.diurnal.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ALSFLFFDIRLILIF

(END) Dow Jones Newswires

October 11, 2022 02:00 ET (06:00 GMT)

Diurnal (LSE:DNL)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Diurnal.
Diurnal (LSE:DNL)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Diurnal.